Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05848765 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Study acronym: REFRACT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Start date changed from estimate of Jul 13, 2023 to Sep 4, 2023v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 31, 2023 to Jul 13, 2023
    • Site details revised at 25 of 25 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Trial Details
NCT Number NCT05848765
Lead Sponsor University of Birmingham
Collaborators: Cancer Research UK, Genmab
Conditions
(from sponsor)		 Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Related terms Lymphoma, Lymphoma, Follicular
Enrollment 284 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov